Vera Therapeutics, Inc. 8-K

What Happened
Vera Therapeutics, Inc. (NASDAQ: VERA) filed an 8-K (dated March 9, 2026) reporting that on March 5, 2026 the board appointed Christopher Hite as a Class III director, with an initial term expiring at the Company’s 2027 Annual Meeting of Stockholders. The filing discloses director compensation tied to his appointment, including a stock option grant and a cash retainer.

Key Details

• Appointment effective March 5, 2026; initial term ends at the 2027 Annual Meeting.
• Mr. Hite received a nonstatutory stock option to purchase 24,937 shares of Class A common stock at a $38.85 exercise price; the option vests monthly over three years, subject to continued service.
• Annual cash retainer of $45,000 (pro‑rated for 2026).
• Beginning with the 2027 Annual Meeting, Mr. Hite will be eligible for an annual option equal to the lesser of 18,000 shares or a grant with a grant‑date fair value up to $400,000; such options vest on the earlier of the first anniversary or the next annual meeting.
• He will enter the company’s standard indemnification agreement; no related‑person transactions or arrangements in connection with his appointment were disclosed.

Why It Matters
This filing informs investors about a board composition change and the associated director compensation. The immediate grant and future annual option eligibility introduce stock‑based compensation and a modest source of potential share dilution if exercised; the cash retainer is a small recurring cash expense. These elements will be reflected in future SEC filings and the company’s compensation disclosures.